Philips/Biomerieux ink point-of-care test partnership
This article was originally published in The Gray Sheet
Firms will jointly develop fully automated, handheld immunoassay diagnostics for hospitals based on Philips' Magnotech biosensor platform under a partnership announced Jan. 7. The initial "co-branded" products, intended to "improve diagnosis and disease management in critical care settings," are slated to debut by 2013 and will be distributed exclusively by Biomerieux, the firms say
You may also be interested in...
Australia’s competition regulator, the ACCC, has granted a conditional dispensation to allow generics industry association the GBMA and brand body Medicines Australia to work together to help address the coronavirus pandemic by sharing information on stock, inventory, manufacturing and the supply chain. However, tender pricing will not be among the subjects discussed.
The UK biotech's CEO tells Scrip that Izana's objective is to treat rapidly deteriorating COVID-19 patients before ICU admission and prior to ventilation.
Exclusive: HBW Insight speaks to HRA Pharma CEO David Wright about the company's plans to become a top-10 global OTC player. Wright reveals that HRA is about to enter Latin America, beginning with Mexico and Brazil, and is currently looking at at least two significant acquisitions to ramp up its expansion plans in the coming months.